Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS

Running, not enrolling · Not applicable

Conditions studied: Leukemia, Acute, AML, Adult, ALL, Adult, Myelodysplastic Syndromes

In brief

The purpose of this study is to estimate the potential benefit of early and continued palliative care (PC) consultation on end of life issues.

Key facts

Study ID

NCT04482894

Run by

University of Virginia

People needed

105

Starts

2020-08-19

Expected to finish

2027-06-01

Last updated by the study team

2026-05-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ability to provide informed consent
• Stated willingness to comply with all study procedures and availability for the duration of the study
• Any of the following:
• Patients with a new diagnosis of AML, ALL, high risk myelodysplastic syndrome (MDS), or high risk chronic myelomonocytic leukemia (CMML) who are age 65 and older.
• OR
• Patients with relapsed AML, ALL, high risk MDS or high risk CMML, ages 18 and older.
• OR
• Patients with refractory AML, ALL, high risk MDS or high risk CMML, ages 18 and older.
• Refractory AML/ALL will be defined as persistent leukemia despite two or more cycles of induction chemotherapy.
• Refractory MDS will be defined according to the 2006 IWG response criteria Refractory CMML will be based on the assessment of the treating investigator.

You may not qualify if…

• Participants must not have a diagnosis of Acute Promyelocytic Leukemia (APL)

Where it is running

• University of Virginia — Charlottesville, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.